Table 4:
Frequencies of Major Features by Reader among HCC versus non-HCC Malignancies with Interrater Reliability Analysis
| Major Feature | HCC (n = 105) |
Non-HCC Malignancy (n = 73) |
p value* | Interpretation | κ Value† | Agreement |
|---|---|---|---|---|---|---|
| Nonrim APHE | … | … | … | … | 0.60 (0.49-0.72) | Moderate |
| R1 | 91 (87%) | 19 (26%) | <0.001 | More common among HCC | … | … |
| R2 | 78 (74%) | 10 (14%) | <0.001 | More common among HCC | … | … |
| Nonperipheral “washout” | … | … | … | … | 0.55 (0.42-0.67) | Moderate |
| R1 | 72 (69%) | 16 (22%) | <0.001 | More common among HCC | … | … |
| R2 | 65 (62%) | 9 (12%) | <0.001 | More common among HCC | … | … |
| Enhancing “capsule” | … | … | … | … | 0.60 (0.48-0.72) | Moderate |
| R1 | 59 (56%) | 15 (21%) | <0.001 | More common among HCC | … | … |
| R2 | 51 (49%) | 7 (10%) | <0.001 | More common among HCC | … | … |
| Size | … | … | … | … | … | … |
| 10-19 mm | … | … | … | … | 0.48 (0.25-0.71) | Moderate |
| R1 | 11 (10%) | 1 (1%) | 0.04 | No difference | … | … |
| R2 | 20 (19%) | 6 (8%) | 0.07 | No difference | … | … |
| ≥ 20 mm | … | … | … | … | 0.48 (0.25-0.71) | Moderate |
| R1 | 94 (90%) | 72 (99%) | 0.04 | No difference | … | … |
| R2 | 85 (81%) | 67 (92%) | 0.07 | No difference | … | … |
| Threshold growth | … | … | … | … | −0.02 (−0.67-0.63) | Poor |
| R1 | 5 (5%) | 2 (3%) | 0.77 | No difference | ||
| R2 | 5 (5%) | 2 (3%) | 0.77 | No difference | ||
| Tumor in vein | … | … | … | … | 0.67 (0.44-0.89) | Substantial |
| R1 | 2 (2%) | 12 (16%) | 0.001 | More common among non-HCC | ||
| R2 | 2 (2%) | 10 (14%) | 0.005 | May be more common among non-HCC** |
*
p values are based on results from Pearson χ2 or Fisher exact test; p < 0.005 represents a significant difference.
**
Falls on the borderline of significance.
†
Data in parentheses represent 95% confidence intervals.
Abbreviations: HCC – hepatocellular carcinoma; APHE – arterial phase hyperenhancement; R1 – reader 1; R2 – reader 2